Kymera Therapeutics Inc. (KYMR): Price and Financial Metrics
GET POWR RATINGS... FREE!
KYMR POWR Grades
- KYMR scores best on the Value dimension, with a Value rank ahead of 60.74% of US stocks.
- KYMR's strongest trending metric is Quality; it's been moving down over the last 178 days.
- KYMR's current lowest rank is in the Growth metric (where it is better than 3.25% of US stocks).
KYMR Stock Summary
- Kymera Therapeutics Inc's stock had its IPO on August 21, 2020, making it an older stock than just 2.2% of US equities in our set.
- Of note is the ratio of Kymera Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 7.99% of US stocks have a lower such ratio.
- KYMR's price/sales ratio is 59.4; that's higher than the P/S ratio of 96.59% of US stocks.
- If you're looking for stocks that are quantitatively similar to Kymera Therapeutics Inc, a group of peers worth examining would be ARCT, INO, NRIX, SGMO, and XENE.
- To check out Kymera Therapeutics Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001815442.
KYMR Valuation Summary
- In comparison to the median Healthcare stock, KYMR's price/sales ratio is 2352.63% higher, now standing at 93.2.
- Over the past 12 months, KYMR's price/sales ratio has gone down 379.8.
- KYMR's price/sales ratio has moved down 379.8 over the prior 12 months.
Below are key valuation metrics over time for KYMR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| KYMR | 2021-08-31 | 93.2 | 12.3 | -54.3 | -53.2 |
| KYMR | 2021-08-30 | 91.7 | 12.1 | -53.4 | -52.3 |
| KYMR | 2021-08-27 | 90.4 | 11.9 | -52.7 | -51.6 |
| KYMR | 2021-08-26 | 87.8 | 11.6 | -51.2 | -50.1 |
| KYMR | 2021-08-25 | 84.4 | 11.1 | -49.2 | -48.1 |
| KYMR | 2021-08-24 | 82.3 | 10.9 | -48.0 | -46.9 |
KYMR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- KYMR has a Quality Grade of C, ranking ahead of 56.47% of graded US stocks.
- KYMR's asset turnover comes in at 0.072 -- ranking 286th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows KYMR's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.072 | 1 | -0.179 |
| 2020-12-31 | 0.113 | 1 | -0.234 |
KYMR Price Target
For more insight on analysts targets of KYMR, see our KYMR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $78.43 | Average Broker Recommendation | 1.45 (Moderate Buy) |
KYMR Stock Price Chart Interactive Chart >
KYMR Price/Volume Stats
| Current price | $15.05 | 52-week high | $69.12 |
| Prev. close | $14.23 | 52-week low | $13.62 |
| Day low | $14.10 | Volume | 798,100 |
| Day high | $15.07 | Avg. volume | 542,568 |
| 50-day MA | $29.99 | Dividend yield | N/A |
| 200-day MA | $47.29 | Market Cap | 778.45M |
Kymera Therapeutics Inc. (KYMR) Company Bio
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Latest KYMR News From Around the Web
Below are the latest news stories about Kymera Therapeutics Inc that investors may wish to consider to help them evaluate KYMR as an investment opportunity.
Morgan Stanley Sticks to Their Hold Rating for Kymera Therapeutics (KYMR)Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Kymera Therapeutics (KYMR – Research Report) today and set a price target of $66.00. The company's shares closed last Wednesday at $38.87. According to TipRanks.com, Purohit is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -32.1% and a 6.7% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Theravance Biopharma, and Foghorn Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kymera Therapeutics with a $74.17 average price target. |
Kymera Therapeutics to Participate in Upcoming March Investor ConferencesWATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the following upcoming virtual investor conferences: Cowen & Co. 42nd Annual Health Care Conference 2022: Fireside Chat with Nello Mainolfi, PhD, Co-Founder, President and CEO on March 8th at 9:50 a.m. ET Gugge |
H.C. Wainwright Keeps a Buy Rating on Kymera Therapeutics (KYMR)H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) today and set a price target of $85.00. The company's shares closed last Friday at $40.07. According to TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.6% and a 33.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. Currently, the analyst consensus on Kymera Therapeutics is a Strong Buy with an average price target of $75.80, a 92.8% upside from current levels. |
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue EstimatesKymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business UpdateCompleted dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines and favorable safety profile. HS and AD patient cohort data expected in 2H22 INDs cleared and Phase 1 clinical studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413), with proof of mechanism data expected in 2022 First disclosure of KT-253, a first-in-class potent and selective MDM2 degrader targ |
KYMR Price Returns
| 1-mo | -51.99% |
| 3-mo | -62.15% |
| 6-mo | -72.89% |
| 1-year | -68.70% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -76.30% |
| 2021 | 2.40% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...